(Q42710172)

5 November 2017

Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib (English)

1 reference

5 November 2017

0 references

M Huang

1

1 reference

5 November 2017

D Thomas

2

1 reference

5 November 2017

M X Li

3

1 reference

5 November 2017

W Feng

4

1 reference

5 November 2017

S M Chan

5

1 reference

5 November 2017

R Majeti

6

1 reference

5 November 2017

B S Mitchell

7

1 reference

5 November 2017

23 July 2013

1 reference

5 November 2017

1 reference

5 November 2017

27

1 reference

5 November 2017

10

1 reference

5 November 2017

1970-1980

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.222

5 November 2017

0 references

cites work

Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

The therapeutic potential of the proteasome in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Myeloma bone disease and proteasome inhibition therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Do reactive oxygen species play a role in myeloid leukemias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Biological responses to arsenic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Alternatively spliced isoforms of TRIP8b differentially control h channel trafficking and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Reactive oxygen species regulate nucleostemin oligomerization and protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Regulation of the nucleocytoplasmic trafficking of viral and cellular proteins by ubiquitin and small ubiquitin-related modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Intrinsic and extrinsic negative regulators of nuclear protein transport processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Nuclear transport: a switch for the oxidative stress-signaling circuit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

The tale of protein lysine acetylation in the cytoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Arsenic-induced oxidative stress and its reversibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

NADPH oxidase-produced superoxide mediates EGFR transactivation by c-Src in arsenic trioxide-stimulated human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.222

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.222

1 reference

Dimensions Publication ID

5 November 2017

0 references

1 reference